Back to top

Alnylam: Neutral Stance Maintained as TTR-CM Growth Slows and Pipeline Remains Early; $370 Price Target Unchanged

Analyst Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma and keeping the price target at $370.00. Michael Ulz has given h...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)